Natalia Rompoti

Real‐world data on the efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis

Evangelia Papadavid, Natalia Rompoti, Konstantinos Theodoropoulos et al. · Journal of the European Academy of Dermatology and Venereology · 2018 · 76 citations

Medicine, Pharmacology, Pharmacotherapy +14

Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort Study

Tiago Torres, L. Puig, Ronald Vender et al. · American Journal of Clinical Dermatology · 2022 · 75 citations · Full text

Medicine, Dermatology, Immunology +16

Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study

Tiago Torres, Andrea Chiricozzi, L. Puig et al. · American Journal of Clinical Dermatology · 2024 · 60 citations · Full text

Medicine, Dermatology, Immunology +15

Real world data from the use of secukinumab in the treatment of moderate‐to‐severe psoriasis, including scalp and palmoplantar psoriasis: A 104‐week clinical study

Natalia Rompoti, Pelagia Katsimbri, G. Kokkalis et al. · Dermatologic Therapy · 2019 · 50 citations

Medicine, Dermatology, Pharmacotherapy +15

Real‐world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response

Natalia Rompoti, Polytimi Sidiropoulou, Pantelis Panagakis et al. · Journal of the European Academy of Dermatology and Venereology · 2020 · 35 citations

Medicine, Dermatology, Pharmacotherapy +13